Organon OGN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Arcoxia | $263M-1.1% | $266M+4.3% | $255M+0.8% | $253M-1.9% | $258M-4.8% | |
| Atozet | $333M+2.5% | $325M-3.0% | $335M-8.2% | $365M-12.9% | $419M-11.6% | |
| Brenzys | $86M+7.5% | $80M+9.6% | $73M-5.2% | $77M+14.9% | $67M-13.0% | |
| Clarinex | $120M-2.4% | $123M+2.5% | $120M-1.6% | $122M-0.8% | $123M-2.4% | |
| Cozaar/Hyzaar | $221M+0.9% | $219M-1.8% | $223M-1.8% | $227M-1.7% | $231M-4.9% | |
| Diprospan | $155M+3.3% | $150M+0.7% | $149M+2.8% | $145M+2.8% | $141M+0.7% | |
| Dulera | $145M-5.2% | $153M-10.0% | $170M-7.6% | $184M-3.2% | $190M-6.4% | |
| Emgality | $196M+12.6% | $174M+6.7% | $163M+15.6% | $141M+9.3% | $129M+20.6% | |
| Follistim AQ | $257M-3.0% | $265M-2.9% | $273M+0.4% | $272M+4.6% | $260M+9.7% | |
| Fosamax | $139M-2.8% | $143M-2.1% | $146M+1.4% | $144M-0.7% | $145M-4.6% | |
| Ganirelix Acetate Injection | $99M-1.0% | $100M-2.9% | $103M-3.7% | $107M0.0% | $107M-1.8% | |
| Hadlima | $249M+8.7% | $229M+12.3% | $204M+12.7% | $181M+13.8% | $159M+12.0% | |
| Jada | $63M-13.7% | $73M+2.8% | $71M+6.0% | $67M+6.3% | $63M+3.3% | |
| Marvelon/Mercilon | $114M-10.2% | $127M-5.2% | $134M+1.5% | $132M-5.7% | $140M+4.5% | |
| Nasonex | $256M-2.7% | $263M-4.0% | $274M-1.1% | $277M+2.2% | $271M-1.8% | |
| Nexplanon/Implanon NXT | $874M-5.1% | $921M-5.1% | $970M-2.0% | $990M-0.2% | $992M+2.9% | |
| NuvaRing | $94M+2.2% | $92M-8.9% | $101M+3.1% | $98M-1.0% | $99M-13.9% | |
| Ontruzant | $86M-13.1% | $99M-13.2% | $114M+10.7% | $103M-14.2% | $120M-14.9% | |
| Other Biosimilars | $52M+57.6% | $33M+17.9% | $28M+7.7% | $26M— | —— | |
| Other Cardiovascular | $123M-1.6% | $125M-4.6% | $131M+3.1% | $127M+1.6% | $125M-6.0% | |
| Other Non-Opiod Pain, Bone and Dermatology | $300M0.0% | $300M+1.4% | $296M+2.1% | $290M+0.7% | $288M-1.4% | |
| Other Respiratory | $50M-2.0% | $51M-10.5% | $57M-3.4% | $59M+1.7% | $58M+7.4% | |
| Other | $347M+2.7% | $338M-0.6% | $340M+1.2% | $336M+4.7% | $321M-1.8% | |
| Other | $77M-4.9% | $81M-15.6% | $96M-5.0% | $101M-7.3% | $109M-6.0% | |
| Other Women's Health | $177M+1.7% | $174M+4.2% | $167M+1.8% | $164M+5.1% | $156M0.0% | |
| Propecia | $123M+3.4% | $119M-3.3% | $123M+4.2% | $118M+3.5% | $114M+2.7% | |
| Proscar | $99M+2.1% | $97M+2.1% | $95M+4.4% | $91M-1.1% | $92M-2.1% | |
| Renflexis | $251M0.0% | $251M-1.2% | $254M-0.8% | $256M-2.3% | $262M-4.4% | |
| Rosuzet | $26M+8.3% | $24M-17.2% | $29M-14.7% | $34M-8.1% | $37M-24.5% | |
| Singulair | $218M-13.5% | $252M-9.0% | $277M-10.4% | $309M-8.0% | $336M-6.7% | |
| Vtama | $129M+0.8% | $128M+26.7% | $101M+50.7% | $67M+86.1% | $36M+200% | |
| Vytorin | $98M-2.0% | $100M-1.0% | $101M-1.0% | $102M-1.0% | $103M-4.6% | |
| Zetia | $344M+0.6% | $342M+4.0% | $329M+3.8% | $317M-0.3% | $318M+0.3% | |
| Revenue by Geography | ||||||
| Asia Pacific and Japan | $975M-2.5% | $1B+0.4% | $996M-0.9% | $1.01B-1.0% | $1.02B-3.4% | |
| China | $819M-1.2% | $829M-1.3% | $840M+0.8% | $833M-1.4% | $845M-0.2% | |
| Europe and Canada | $1.65B+2.2% | $1.62B-0.9% | $1.63B-1.2% | $1.65B-2.2% | $1.69B-4.2% | |
| Latin America, Middle East, Russia, and Africa | $1.08B+0.7% | $1.07B-0.4% | $1.08B+4.2% | $1.03B+3.4% | $1B-3.3% | |
| Other | $85M-7.6% | $92M-14.8% | $108M-8.5% | $118M-9.9% | $131M-3.0% | |
| U.S. | $1.55B-3.4% | $1.6B-2.7% | $1.65B+0.5% | $1.64B+1.6% | $1.61B+2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Organon break its business down?
- Organon (OGN) reports revenue by product across 33 parts — Arcoxia, Atozet, Brenzys, Clarinex and Cozaar/Hyzaar. Each is extracted from the segment footnotes and tracked over time.
- Where does Organon's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Organon's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.